

In the claims:

1.-6. (canceled)

7. (Canceled)

8. (Canceled)

9. (Currently amended) A drug comprising a 2-imidazolyl disulfide and a pharmaceutically acceptable carrier for injection, said 2-imidazolyl disulfide being formulated in a suitable dosage amount useful in reducing or eliminating thioredoxin-associated apoptosis inhibition ~~The drug of claim 7~~, wherein said 2-imidazolyl disulfide is 1-methylpropyl 2-imidazolyl disulfide.

10. (Currently amended) A drug comprising a 2-imidazolyl disulfide and a pharmaceutically acceptable carrier, for injection said 2-imidazolyl disulfide being formulated in a suitable dosage amount useful in inhibiting thioredoxin stimulated cell growth ~~The drug of claim 8~~, wherein said 2-imidazolyl disulfide is 1-methylpropyl 2-imidazolyl disulfide.

11. (Currently amended) The drug of claim 7 ~~9~~, wherein said 2-imidazolyl disulfide inhibits tumor growth.

12. (Previously presented) The drug of claim 8 ~~10~~, wherein said 2-imidazolyl disulfide inhibits tumor growth.

13. (Previously presented) The drug of claim 9, wherein said 1-methylpropyl-2-imidazolyl disulfide inhibits thioredoxin.

14. (Previously presented) The drug of claim 10, wherein said 1-methylpropyl-2-imidazolyl disulfide inhibits thioredoxin.

15. (Previously presented) The drug of claim 9, wherein said 1-methylpropyl-2-imidazolyl disulfide irreversibly binds to thioredoxin.

16. (Previously presented) The drug of claim 10 wherein said 1-methylpropyl-2-imidazolyl disulfide irreversibly binds to thioredoxin.

17. (Previously presented) The drug of claim 9, wherein said 1-methylpropyl-2-imidazolyl disulfide irreversibly binds to Cys⁷³ of thioredoxin.

18. (Previously presented) The drug of claim 10, wherein said 1-methylpropyl-2-imidazolyl disulfide irreversibly binds to Cys⁷³ of thioredoxin.

19.-20. (Canceled)

21. (Currently amended) A drug comprising a 2-imidazolyl disulfide and an acceptable carrier for oral administration, said 2-imidazolyl disulfide being formulated in a suitable dosage amount useful in reducing or eliminating thioredoxin-associated apoptosis inhibition ~~The drug of claim 19~~, wherein said 2-imidazolyl disulfide is 1-methylpropyl 2-imidazolyl disulfide.

22. (Currently amended) A drug comprising a 2-imidazolyl disulfide and an acceptable carrier for oral administration, said 2-imidazolyl disulfide being formulated in a suitable dosage amount useful in inhibiting thioredoxin stimulated cell growth ~~The drug of claim 20~~, wherein said 2-imidazolyl disulfide is 1-methylpropyl 2-imidazolyl disulfide.

23. (Currently amended) The drug of claim ~~19~~ 21, wherein said 2-imidazolyl disulfide inhibits tumor growth.

24. (Currently amended) The drug of claim ~~20~~ 22, wherein said 2-imidazolyl disulfide inhibits tumor growth.

25. (Previously presented) The drug of claim 21, wherein said 1-methylpropyl-2-imidazolyl disulfide inhibits thioredoxin.

26. (Previously presented) The drug of claim 22, wherein said 1-methylpropyl-2-imidazolyl disulfide inhibits thioredoxin.

27. (Previously presented) The drug of claim 21, wherein said 1-methylpropyl-2-imidazolyl disulfide irreversibly binds to thioredoxin.

28. (Previously presented) The drug of claim 22, wherein said 1-methylpropyl-2-imidazolyl disulfide irreversibly binds to thioredoxin.

29. (Previously presented) The drug of claim 21, wherein said 1-methylpropyl-2-imidazolyl disulfide irreversibly binds to Cys⁷³ of thioredoxin.

30. (Previously presented) The drug of claim 22, wherein said 1-methylpropyl-2-imidazolyl disulfide irreversibly binds to Cys⁷³ of thioredoxin.

31. (Previously presented) The drug of claim 9, comprising 15-45 mg/m² of 1-methylpropyl-2-imidazolyl disulfide.

32. (Previously presented) The drug of claim 10, comprising 15-45 mg/m² of 1-methylpropyl-2-imidazolyl disulfide.

33. (Previously presented) The drug of claim 9, wherein said 1-methylpropyl-2-imidazolyl disulfide is injected at 15mg/ m².

34. (Previously presented) The drug of claim 10, wherein said 1-methylpropyl-2-imidazolyl disulfide is injected at 15 mg/m².

35. (Previously presented) The drug of claim 9, wherein said 1-methylpropyl-2-imidazolyl disulfide is injected at 30 mg/m².

36. (Previously presented) The drug of claim 10, wherein said 1-methylpropyl-2-imidazolyl disulfide is injected at 30 mg/m².

37. (Previously presented) The drug of claim 9, wherein said 1-methylpropyl-2-imidazolyl disulfide is injected at 45 mg/m².

38. (Previously presented) The drug of claim 10, wherein said 1-methylpropyl-2-imidazolyl disulfide is injected at 45 mg/m².

39. (Previously presented) The drug of claim 21, wherein said 1-methylpropyl-2-imidazolyl disulfide is administered orally up to 250 mg/kg.

40. (Previously presented) The drug of claim 22, wherein said 1-methylpropyl-2-imidazolyl disulfide is administered orally up to 250 mg/kg.